MDR M. tuberculosis outbreak clone in Eswatini missed by Xpert has elevated bedaquiline resistance dated to the pre-treatment era
Open Access
- 25 November 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Genome Medicine
- Vol. 12 (1), 1-11
- https://doi.org/10.1186/s13073-020-00793-8
Abstract
Multidrug-resistant (MDR) Mycobacterium tuberculosis complex strains not detected by commercial molecular drug susceptibility testing (mDST) assays due to the RpoB I491F resistance mutation are threatening the control of MDR tuberculosis (MDR-TB) in Eswatini. We investigate the evolution and spread of MDR strains in Eswatini with a focus on bedaquiline (BDQ) and clofazimine (CFZ) resistance using whole-genome sequencing in two collections ((1) national drug resistance survey, 2009–2010; (2) MDR strains from the Nhlangano region, 2014–2017). MDR strains in collection 1 had a high cluster rate (95%, 117/123 MDR strains) with 55% grouped into the two largest clusters (gCL3, n = 28; gCL10, n = 40). All gCL10 isolates, which likely emerged around 1993 (95% highest posterior density 1987–1998), carried the mutation RpoB I491F that is missed by commercial mDST assays. In addition, 21 (53%) gCL10 isolates shared a Rv0678 M146T mutation that correlated with elevated minimum inhibitory concentrations (MICs) to BDQ and CFZ compared to wild type isolates. gCL10 isolates with the Rv0678 M146T mutation were also detected in collection 2. The high clustering rate suggests that transmission has been driving the MDR-TB epidemic in Eswatini for three decades. The presence of MDR strains in Eswatini that are not detected by commercial mDST assays and have elevated MICs to BDQ and CFZ potentially jeopardizes the successful implementation of new MDR-TB treatment guidelines. Measures to limit the spread of these outbreak isolates need to be implemented urgently.Keywords
Funding Information
- European Commission (FP7-223681)
- Deutsche Forschungsgemeinschaft (EXC 2167)
- Leibniz-Gemeinschaft (EvoLung)
- Bundesministerium für Bildung und Forschung (DZIF)
This publication has 36 references indexed in Scilit:
- Countrywide roll-out of Xpert® MTB/RIF in Swaziland: the first three years of implementationPublic Health Action, 2015
- The 2014 Garrod Lecture: EUCAST – are we heading towards international agreement?Journal of Antimicrobial Chemotherapy, 2015
- The Resistant-Population Cutoff (RCOFF): a New Concept for Improved Characterization of Antimicrobial Susceptibility Patterns of Non-Wild-Type Bacterial PopulationsJournal of Clinical Microbiology, 2015
- Detection of Drug-Resistant Tuberculosis by Xpert MTB/RIF in SwazilandThe New England Journal of Medicine, 2015
- Long walk to treatment for XDR tuberculosis in South AfricaThe Lancet, 2014
- Whole Genome Sequencing versus Traditional Genotyping for Investigation of a Mycobacterium tuberculosis Outbreak: A Longitudinal Molecular Epidemiological StudyPLoS Medicine, 2013
- Importance of the Genetic Diversity within the Mycobacterium tuberculosis Complex for the Development of Novel Antibiotics and Diagnostic Tests of Drug ResistanceAntimicrobial Agents and Chemotherapy, 2012
- Online tools for polyphasic analysis of Mycobacterium tuberculosis complex genotyping data: Now and nextInfection, Genetics and Evolution, 2012
- High Prevalence of Multidrug-Resistant Tuberculosis, Swaziland, 2009–2010Emerging Infectious Diseases, 2012
- The European Nucleotide ArchiveNucleic Acids Research, 2010